蔗糖氢氧化氧铁与碳酸司维拉姆对透析患者CKD-MBD指标的影响
本分析基于一项随机3期研究的事后分析,纳入完成≥1年持续治疗的549例透析高磷血症患者,评估蔗糖氢氧化氧铁或碳酸司维拉姆治疗对CKD-MBD指标的影响。结果显示两种磷结合剂均显著降低血磷约30%和FGF-23约64%,骨形成标志物升高,提示对骨代谢有益。
要点
- 两种磷结合剂治疗1年显著降低血磷约30%和FGF-23约64%。
- iPTH在24周显著下降但52周回落至近基线,血钙变化极小。
- 骨形成标志物升高,骨吸收标志物TRAP5b显著下降。
核心结论
- 蔗糖氢氧化氧铁或碳酸司维拉姆治疗1年显著降低透析患者血清FGF-23。
- 骨形成标志物升高趋势提示对骨代谢有益。
研究设计与样本
- 随机3期研究的事后分析,患者按2:1随机接受蔗糖氢氧化氧铁1.0-3.0 g/日或碳酸司维拉姆2.4-14.4 g/日。
- 纳入完成≥1年持续治疗的549例透析高磷血症患者,因两组CKD-MBD结局相似而汇总分析。
主要发现
- 磷结合剂治疗使血清磷持续显著降低30%(P < 0.001)。
- 中位完整FGF-23在1年内显著下降64%(P < 0.001)。
- iPTH在24周显著下降(P < 0.001),但52周时回落至近基线水平。
- TRAP5b显著下降(P < 0.001),CTx短暂升高但52周回到基线。
- 骨特异性碱性磷酸酶和骨钙素在1年治疗期间均升高。
临床怎么用
- 对于透析高磷血症患者,可选用蔗糖氢氧化氧铁或碳酸司维拉姆降低血磷和FGF-23。
- 治疗期间需关注iPTH先降后回升及骨代谢标志物的动态变化。
局限性
- 为事后分析,仅纳入完成≥1年治疗的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of hyperphosphataemia is the primary goal of chronic kidney disease-mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate ('sevelamer') on CKD-MBD indices among dialysis patients with hyperphosphataemia. METHODS: After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0-3.0 g/day (n = 710) or sevelamer 2.4-14.4 g/day (n = 349) for up to 24 weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ≥1 year of continuous treatment (n = 549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis. RESULTS: Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P < 0.001). Median intact fibroblast growth factor-23 (FGF-23) also significantly decreased (P < 0.001) by 64% over 1 year. Intact parathyroid hormone decreased significantly after 24 weeks (P < 0.001), but levels returned to near baseline values by Week 52; minimal changes in serum calcium were observed. Of the bone resorption markers evaluated, tartrate-resistant acid phosphatase 5b (TRAP5b) decreased significantly (P < 0.001), whereas CTx increased transiently but returned to baseline levels by Week 52. The bone formation markers bone-specific alkaline phosphatase and osteocalcin both increased over 1 year of treatment. CONCLUSIONS: Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD. The trend towards increased bone formation marker levels indicates a beneficial effect on bone metabolism.
引用
- Ketteler M, Sprague SM, Covic AC, et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019. PMID: 29846719. doi:10.1093/ndt/gfy127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。